15 completed, 3 unknown, 2 recruiting. 6 Phase 3, 4 Not applicable, 4 Phase 4, 3 Phase 2, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Unknown 2 |
| Not applicable | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 4 | 4 | Completed 4 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Early Phase 1 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Intertrigo: new trials by email Literature Review of Intertrigo trials Research Report on Intertrigo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates in Faisalabad, Pakistan In vitro antifungal susceptibility testing - Dermatophytosis, Tinea Corporis | Recruiting | Dr. Amara Safdar | 120 | 2026-10-02 | 2026-10-27 | |
| A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis Intra-Lesional MMR Immunotherapy - Tinea Corporis, Tinea Cruris | Not applicable | Recruiting | Abeer Mohamed Abdelaziz Elkholy | 50 | 2025-12-09 | 2025-12-31 |
| Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea CrurisAbstract Topical Oxiconazole cream, Topical Clotrimazole cream - Tinea Cruris | Early Phase 1 | Completed | Hayat Abad Medical Complex, Peshawar | 386 | 2025-05-15 | 2026-02-27 |
| Seeing Red: Clinical Assessment Tools for Clinical Trial Decision Support Screening - Incontinence-associated Dermatitis, Moisture Associated Skin Damage | Not applicable | Unknown | Scotiaderm | 20 | 2024-05-01 | 2024-04-16 |
| Efficacy and Safety of Terbinafine and Itraconazole Terbinafine Tablets, Itraconazole - Tinea Corporis, Tinea Cruris | Phase 2 / Phase 3 | Unknown | Dhaka Medical College | 150 | 2023-05-01 | 2023-05-31 |
| Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis UHE-103 Cream, Naftin (naftifine hydrochloride) Cream - Tinea Cruris, Tinea Pedis | Phase 1 | Completed | Therapeutics, Inc. | 42 | 2022-02-17 | 2024-04-10 |
| Tapioca Starch Stimutex AS, Aloe Barbadensis, Rose Hip Oil, Allantoin Comparing With Topical 1% Hydrocortisone Cream Liquid powder, Hydrocortisone cream 1% - Intertrigo | Phase 4 | Completed | Mahidol University | 40 | 2019-10-01 | 2021-04-20 |
| Enhancing SKIN Health and Safety in Aged CARE Implementation of skin care algorithm - Xerosis Cutis, Dry Skin | Not applicable | Completed | PD Dr. Jan Kottner | 405 | 2018-10-01 | 2021-08-09 |
| Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris Luliconazole Cream 1% - Tinea Pedis, Tinea Cruris | Phase 4 | Completed | Bausch Health Americas, Inc. | 30 | 2015-12-02 | 2019-11-27 |
| Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris Omeprazole 40 mg, Luliconazole Cream 1% - Tinea Pedis, Tinea Cruris | Phase 4 | Completed | Bausch & Lomb Incorporated | 20 | 2015-02-03 | 2019-11-27 |
| Clinical Trial Comparing Dapaconazole Versus Miconazole in Patients With Tinea Cruris Dapaconazole, Miconazole Nitrate - Tinea Cruris | Phase 2 | Completed | Galeno Desenvolvimento de Pesquisas Clínicas | 51 | 2014-01-29 | 2017-12-02 |
| Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Naftin 1% Cream, Placebo Cream - Tinea Cruris, Jock Itch | Phase 3 | Completed | Merz North America, Inc. | 65 | 2013-08-01 | 2015-04-15 |
| Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis NAFT500 (pediatric), NAFT600 (pediatric), NAFT500 (adult) - Tinea Pedis, Tinea Cruris | Phase 4 | Completed | Merz North America, Inc. | 56 | 2012-10-01 | 2016-07-14 |
| Evaluation of Preclinical Toxicity andTherapeutic Efficacy of Kandhaga Rasayanam in Padarthamarai kandhaga rasayanam - Tinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are Studied | Phase 2 | Completed | National institute of Siddha | 50 | 2012-06-01 | 2014-09-12 |
| Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Clotrimazole - Fungal Infections, Tinea Pedis | Phase 3 | Unknown | Laboratório Teuto Brasileiro S/A | 90 | 2012-04-01 | 2012-04-12 |
| Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Product 33525 - Tinea Pedis, Tinea Cruris | Phase 3 | Completed | Tinea Pharmaceuticals | 604 | 2011-05-01 | 2013-01-23 |
| Topical Antifungal Treatment for Tinea Cruris 33525, Placebo - Tinea Cruris | Phase 3 | Completed | Medicis Global Service Corporation | 483 | 2011-05-01 | 2013-08-28 |
| Washing Without Water: Cost-effectiveness of a Rapidly Spreading Nursing Intervention in Bedridden Patients' Washing without water - Skin Disease | Not applicable | Completed | Betsie van Gaal | 500 | 2011-04-01 | 2017-04-25 |
| Open-Label Pilot Study of the Efficacy and Safety of Vusion Ointment for the Treatment of Intertrigo Vusion - Intertrigo | Early Phase 1 | Completed | Image Dermatology P.C. | 15 | 2010-04-01 | 2011-08-04 |
| Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris NAFT-500, Placebo - Tinea Cruris, Jock Itch | Phase 3 | Completed | Merz North America, Inc. | 334 | 2008-09-01 | 2013-04-22 |
Tinea Cruris (15) · Tinea (8) · Tinea Pedis (8) · Aggression (1) · Dermatitis (1) · Erythema (1) · Mycoses (1) · Onychomycosis (1) · Pressure Ulcer (1) · Pruritus (1) · Skin Diseases (1) · tinea barbae (1)
Skin Diseases, Eczematous (20) · Skin and Connective Tissue Diseases (20) · Dermatitis (19) · Skin Diseases (19) · Bacterial Infections and Mycoses (15) · Dermatomycoses (15) · Infections (15) · Skin Diseases, Infectious (15) · Mycoses (14) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (10) · Skin Manifestations (10) · Foot Dermatoses (8) · Foot Diseases (8)
naftifine (3) · 1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1H-imidazole (1) · Clotrimazole (1) · FR dental filling (1) · Hydrotherapy (1) · Itraconazole (1) · Mass Screening (1) · Measles-Mumps-Rubella Vaccine (1) · Miconazole (1) · Omeprazole (1) · Terbinafine (1) · Therapeutic Irrigation (1)
Merz North America, Inc. (3) · Abeer Mohamed Abdelaziz Elkholy (1) · Bausch & Lomb Incorporated (1) · Bausch Health Americas, Inc. (1) · Betsie van Gaal (1) · Dhaka Medical College (1) · Dr. Amara Safdar (1) · Galeno Desenvolvimento de Pesquisas Clínicas (1) · Hayat Abad Medical Complex, Peshawar (1) · Image Dermatology P.C. (1) · Laboratório Teuto Brasileiro S/A (1) · Mahidol University (1) · Medicis Global Service Corporation (1) · National institute of Siddha (1) · PD Dr. Jan Kottner (1)
United States (7) · Honduras (5) · Belize (3) · Dominican Republic (3) · Puerto Rico (3) · Brazil (2) · El Salvador (2) · Pakistan (2) · Egypt (1) · Germany (1) · India (1) · Netherlands (1) · Thailand (1)
Anya Loncaric (2) · Alan Fleischer, MD (1) · Dr Fahad Khan (1) · Jan Kottner, Prof. Dr. (1) · Jeanine B. Downie, M.D. (1) · Kalsoom Jawaid, MBBS, FCPS, CMT (1) · Kanokvalai Kulthanan, M.D. (1) · Lawrence Parish, MD (1) · Ron Staugaard (1) · Stefan Plaum, MD (1) · Theo van Achterberg, PhD (1) · Tony Andrasfay (1)
PMID 21968664, PMID 25173772, PMID 31142364, PMID 36898269, PMID 37956524, PMID 38360494